The US Food and Drug Administration (FDA) has approved Celcuity’s drug, gedatolisib, branded as Revtorpyk, for an advanced form of breast cancer. This approval is based on late-stage data showing that Revtorpyk, when combined with Pfizer’s Ibrance and fulvestrant, reduced the risk of disease progression or death by 76% compared with fulvestrant alone.
Treatment Details
Revtorpyk is intended to treat patients with advanced breast cancer whose tumors have low levels of a protein called HER2 and no mutation in a gene called PIK3CA, and whose disease has worsened after hormone therapy and a CDK inhibitor, a type of therapy. Patients receiving the combination remained progression-free for a median of 9.3 months, compared with 2.0 months for patients receiving fulvestrant alone.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
